US Physical Therapy Analyst Ratings
Barrington Maintains US Physical Therapy(USPH.US) With Buy Rating, Cuts Target Price to $108
BofA Securities Maintains US Physical Therapy(USPH.US) With Buy Rating, Cuts Target Price to $114
Maintaining 'Buy' Rating on US Physical Therapy Amid Cost Pressures and Revenue Growth
Analysts' Top Healthcare Picks: US Physical Therapy (USPH), Exact Sciences (EXAS)
Buy Rating for US Physical Therapy: Strong Performance and Positive Growth Outlook
Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), US Physical Therapy (USPH)
US Physical Therapy Analyst Ratings
JP Morgan Maintains Overweight on US Physical Therapy, Raises Price Target to $117
Barrington Research Maintains Outperform on US Physical Therapy, Raises Price Target to $122
US Physical Therapy Analyst Ratings
Barrington Ups Price Target on U.S. Physical Therapy to $122 From $120 After Strong Q4 Beat, Keeps Outperform Rating
US Physical Therapy Analyst Ratings
JP Morgan Maintains Overweight on US Physical Therapy, Lowers Price Target to $99
US Physical Therapy Analyst Ratings
US Physical Therapy Analyst Ratings
Barrington Cuts Price Target on U.S. Physical Therapy to $111 From $124 on 'Tough Stock Market Environment', Reiterates Outperform Rating
Analysts Offer Insights on Healthcare Companies: US Physical Therapy (USPH) and CareDx (CDNA)
Potential Growth and Buy Rating for US Physical Therapy Despite Lower Q4 Outlook and Adjusted Price Objective
US Physical Therapy Analyst Ratings